Failure to recognize antigens released by tumor cells or problems with antigen processing and presentation can disrupt the anti-tumor response and lead to therapeutic failure of ICIs (Jhunjhunwala et al., 2021), providing a conflicting theoretical rationale for the association of BBR with anti-PD-L1 antibodies. Here, CD274 is linked to neoplasm.